Taysha Gene Therapies Inc’s recent filing unveils that its 10% Owner Manning Paul B acquired Company’s shares for reported $3.0 million on Jun 27 ’24. In the deal valued at $2.25 per share,1,333,333 shares were bought. As a result of this transaction, Manning Paul B now holds 1,333,333 shares worth roughly $2.71 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BMO Capital Markets initiated its Taysha Gene Therapies Inc [TSHA] rating to an Outperform in a research note published on June 27, 2024; the price target was $5. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in early April with a ‘”an Overweight”‘ rating. Jefferies also remained covering TSHA and has decreased its forecast on February 01, 2023 with a “Hold” recommendation from previously “Buy” rating. Morgan Stanley revised its rating on January 27, 2023. It rated TSHA as “an Equal-weight” which previously was an “an Overweight”.
Price Performance Review of TSHA
On Tuesday, Taysha Gene Therapies Inc [NASDAQ:TSHA] saw its stock jump 1.00% to $2.03. Over the last five days, the stock has lost -19.44%. Taysha Gene Therapies Inc shares have risen nearly 14.69% since the year began. Nevertheless, the stocks have risen 24.54% over the past one year. While a 52-week high of $4.32 was reached on 06/13/24, a 52-week low of $1.19 was recorded on 11/05/24. SMA at 50 days reached $2.13, while 200 days put it at $2.44.
Levels Of Support And Resistance For TSHA Stock
The 24-hour chart illustrates a support level at 1.97, which if violated will result in even more drops to 1.92. On the upside, there is a resistance level at 2.09. A further resistance level may holdings at 2.16. The Relative Strength Index (RSI) on the 14-day chart is 42.16, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.47, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.52%. Stochastics %K at 3.27% indicates the stock is a buying.
How much short interest is there in Taysha Gene Therapies Inc?
A steep rise in short interest was recorded in Taysha Gene Therapies Inc stocks on 2024-11-29, dropping by -1.97 million shares to a total of 15.67 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-31 was 17.64 million shares. There was a decline of -12.56%, which implies that there is a negative sentiment for the stock.
